Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects

Abstract Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeuti...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Antoni Torres [verfasserIn] Anna Motos [verfasserIn] Denise Battaglini [verfasserIn] Gianluigi Li Bassi [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2018

Schlagwörter:	Pseudomonas aeruginosa Amikacin Ventilator-associated pneumonia Gram-negative bacteria

Übergeordnetes Werk:	In: Critical Care - BMC, 2015, 22(2018), 1, Seite 6
Übergeordnetes Werk:	volume:22 ; year:2018 ; number:1 ; pages:6

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.1186/s13054-018-1958-4

Katalog-ID:	DOAJ073469041

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ073469041
003	DE-627
005	20230309115127.0
007	cr uuu---uuuuu
008	230228s2018 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1186/s13054-018-1958-4 \|2 doi
035			\|a (DE-627)DOAJ073469041
035			\|a (DE-599)DOAJf67bf3dbc05f48c084cbe29fdc19aaee
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC86-88.9
100	0		\|a Antoni Torres \|e verfasserin \|4 aut
245	1	0	\|a Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects
264		1	\|c 2018
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Abstract Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials.
650		4	\|a Pseudomonas aeruginosa
650		4	\|a Amikacin
650		4	\|a Ventilator-associated pneumonia
650		4	\|a Gram-negative bacteria
653		0	\|a Medical emergencies. Critical care. Intensive care. First aid
700	0		\|a Anna Motos \|e verfasserin \|4 aut
700	0		\|a Denise Battaglini \|e verfasserin \|4 aut
700	0		\|a Gianluigi Li Bassi \|e verfasserin \|4 aut
773	0	8	\|i In \|t Critical Care \|d BMC, 2015 \|g 22(2018), 1, Seite 6 \|w (DE-627)331258269 \|w (DE-600)2051256-9 \|x 1466609X \|7 nnns
773	1	8	\|g volume:22 \|g year:2018 \|g number:1 \|g pages:6
856	4	0	\|u https://doi.org/10.1186/s13054-018-1958-4 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/f67bf3dbc05f48c084cbe29fdc19aaee \|z kostenfrei
856	4	0	\|u http://link.springer.com/article/10.1186/s13054-018-1958-4 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1364-8535 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 22 \|j 2018 \|e 1 \|h 6

Indexfelder

author_variant	a t at a m am d b db g l b glb
matchkey_str	article:1466609X:2018----::naeaiaifreeermeaieumnrifcinitenesvcruicr
hierarchy_sort_str	2018
callnumber-subject-code	RC
publishDate	2018
allfields	10.1186/s13054-018-1958-4 doi (DE-627)DOAJ073469041 (DE-599)DOAJf67bf3dbc05f48c084cbe29fdc19aaee DE-627 ger DE-627 rakwb eng RC86-88.9 Antoni Torres verfasserin aut Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials. Pseudomonas aeruginosa Amikacin Ventilator-associated pneumonia Gram-negative bacteria Medical emergencies. Critical care. Intensive care. First aid Anna Motos verfasserin aut Denise Battaglini verfasserin aut Gianluigi Li Bassi verfasserin aut In Critical Care BMC, 2015 22(2018), 1, Seite 6 (DE-627)331258269 (DE-600)2051256-9 1466609X nnns volume:22 year:2018 number:1 pages:6 https://doi.org/10.1186/s13054-018-1958-4 kostenfrei https://doaj.org/article/f67bf3dbc05f48c084cbe29fdc19aaee kostenfrei http://link.springer.com/article/10.1186/s13054-018-1958-4 kostenfrei https://doaj.org/toc/1364-8535 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 22 2018 1 6
spelling	10.1186/s13054-018-1958-4 doi (DE-627)DOAJ073469041 (DE-599)DOAJf67bf3dbc05f48c084cbe29fdc19aaee DE-627 ger DE-627 rakwb eng RC86-88.9 Antoni Torres verfasserin aut Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials. Pseudomonas aeruginosa Amikacin Ventilator-associated pneumonia Gram-negative bacteria Medical emergencies. Critical care. Intensive care. First aid Anna Motos verfasserin aut Denise Battaglini verfasserin aut Gianluigi Li Bassi verfasserin aut In Critical Care BMC, 2015 22(2018), 1, Seite 6 (DE-627)331258269 (DE-600)2051256-9 1466609X nnns volume:22 year:2018 number:1 pages:6 https://doi.org/10.1186/s13054-018-1958-4 kostenfrei https://doaj.org/article/f67bf3dbc05f48c084cbe29fdc19aaee kostenfrei http://link.springer.com/article/10.1186/s13054-018-1958-4 kostenfrei https://doaj.org/toc/1364-8535 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 22 2018 1 6
allfields_unstemmed	10.1186/s13054-018-1958-4 doi (DE-627)DOAJ073469041 (DE-599)DOAJf67bf3dbc05f48c084cbe29fdc19aaee DE-627 ger DE-627 rakwb eng RC86-88.9 Antoni Torres verfasserin aut Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials. Pseudomonas aeruginosa Amikacin Ventilator-associated pneumonia Gram-negative bacteria Medical emergencies. Critical care. Intensive care. First aid Anna Motos verfasserin aut Denise Battaglini verfasserin aut Gianluigi Li Bassi verfasserin aut In Critical Care BMC, 2015 22(2018), 1, Seite 6 (DE-627)331258269 (DE-600)2051256-9 1466609X nnns volume:22 year:2018 number:1 pages:6 https://doi.org/10.1186/s13054-018-1958-4 kostenfrei https://doaj.org/article/f67bf3dbc05f48c084cbe29fdc19aaee kostenfrei http://link.springer.com/article/10.1186/s13054-018-1958-4 kostenfrei https://doaj.org/toc/1364-8535 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 22 2018 1 6
allfieldsGer	10.1186/s13054-018-1958-4 doi (DE-627)DOAJ073469041 (DE-599)DOAJf67bf3dbc05f48c084cbe29fdc19aaee DE-627 ger DE-627 rakwb eng RC86-88.9 Antoni Torres verfasserin aut Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials. Pseudomonas aeruginosa Amikacin Ventilator-associated pneumonia Gram-negative bacteria Medical emergencies. Critical care. Intensive care. First aid Anna Motos verfasserin aut Denise Battaglini verfasserin aut Gianluigi Li Bassi verfasserin aut In Critical Care BMC, 2015 22(2018), 1, Seite 6 (DE-627)331258269 (DE-600)2051256-9 1466609X nnns volume:22 year:2018 number:1 pages:6 https://doi.org/10.1186/s13054-018-1958-4 kostenfrei https://doaj.org/article/f67bf3dbc05f48c084cbe29fdc19aaee kostenfrei http://link.springer.com/article/10.1186/s13054-018-1958-4 kostenfrei https://doaj.org/toc/1364-8535 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 22 2018 1 6
allfieldsSound	10.1186/s13054-018-1958-4 doi (DE-627)DOAJ073469041 (DE-599)DOAJf67bf3dbc05f48c084cbe29fdc19aaee DE-627 ger DE-627 rakwb eng RC86-88.9 Antoni Torres verfasserin aut Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials. Pseudomonas aeruginosa Amikacin Ventilator-associated pneumonia Gram-negative bacteria Medical emergencies. Critical care. Intensive care. First aid Anna Motos verfasserin aut Denise Battaglini verfasserin aut Gianluigi Li Bassi verfasserin aut In Critical Care BMC, 2015 22(2018), 1, Seite 6 (DE-627)331258269 (DE-600)2051256-9 1466609X nnns volume:22 year:2018 number:1 pages:6 https://doi.org/10.1186/s13054-018-1958-4 kostenfrei https://doaj.org/article/f67bf3dbc05f48c084cbe29fdc19aaee kostenfrei http://link.springer.com/article/10.1186/s13054-018-1958-4 kostenfrei https://doaj.org/toc/1364-8535 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 22 2018 1 6
language	English
source	In Critical Care 22(2018), 1, Seite 6 volume:22 year:2018 number:1 pages:6
sourceStr	In Critical Care 22(2018), 1, Seite 6 volume:22 year:2018 number:1 pages:6
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Pseudomonas aeruginosa Amikacin Ventilator-associated pneumonia Gram-negative bacteria Medical emergencies. Critical care. Intensive care. First aid
isfreeaccess_bool	true
container_title	Critical Care
authorswithroles_txt_mv	Antoni Torres @@aut@@ Anna Motos @@aut@@ Denise Battaglini @@aut@@ Gianluigi Li Bassi @@aut@@
publishDateDaySort_date	2018-01-01T00:00:00Z
hierarchy_top_id	331258269
id	DOAJ073469041
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ073469041</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309115127.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2018 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s13054-018-1958-4</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ073469041</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJf67bf3dbc05f48c084cbe29fdc19aaee</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC86-88.9</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Antoni Torres</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pseudomonas aeruginosa</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Amikacin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ventilator-associated pneumonia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gram-negative bacteria</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medical emergencies. Critical care. Intensive care. First aid</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna Motos</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Denise Battaglini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gianluigi Li Bassi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Critical Care</subfield><subfield code="d">BMC, 2015</subfield><subfield code="g">22(2018), 1, Seite 6</subfield><subfield code="w">(DE-627)331258269</subfield><subfield code="w">(DE-600)2051256-9</subfield><subfield code="x">1466609X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:22</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/s13054-018-1958-4</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/f67bf3dbc05f48c084cbe29fdc19aaee</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://link.springer.com/article/10.1186/s13054-018-1958-4</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1364-8535</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">22</subfield><subfield code="j">2018</subfield><subfield code="e">1</subfield><subfield code="h">6</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Antoni Torres
spellingShingle	Antoni Torres misc RC86-88.9 misc Pseudomonas aeruginosa misc Amikacin misc Ventilator-associated pneumonia misc Gram-negative bacteria misc Medical emergencies. Critical care. Intensive care. First aid Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects
authorStr	Antoni Torres
ppnlink_with_tag_str_mv	@@773@@(DE-627)331258269
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC86-88
illustrated	Not Illustrated
issn	1466609X
topic_title	RC86-88.9 Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects Pseudomonas aeruginosa Amikacin Ventilator-associated pneumonia Gram-negative bacteria
topic	misc RC86-88.9 misc Pseudomonas aeruginosa misc Amikacin misc Ventilator-associated pneumonia misc Gram-negative bacteria misc Medical emergencies. Critical care. Intensive care. First aid
topic_unstemmed	misc RC86-88.9 misc Pseudomonas aeruginosa misc Amikacin misc Ventilator-associated pneumonia misc Gram-negative bacteria misc Medical emergencies. Critical care. Intensive care. First aid
topic_browse	misc RC86-88.9 misc Pseudomonas aeruginosa misc Amikacin misc Ventilator-associated pneumonia misc Gram-negative bacteria misc Medical emergencies. Critical care. Intensive care. First aid
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Critical Care
hierarchy_parent_id	331258269
hierarchy_top_title	Critical Care
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)331258269 (DE-600)2051256-9
title	Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects
ctrlnum	(DE-627)DOAJ073469041 (DE-599)DOAJf67bf3dbc05f48c084cbe29fdc19aaee
title_full	Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects
author_sort	Antoni Torres
journal	Critical Care
journalStr	Critical Care
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2018
contenttype_str_mv	txt
container_start_page	6
author_browse	Antoni Torres Anna Motos Denise Battaglini Gianluigi Li Bassi
container_volume	22
class	RC86-88.9
format_se	Elektronische Aufsätze
author-letter	Antoni Torres
doi_str_mv	10.1186/s13054-018-1958-4
author2-role	verfasserin
title_sort	inhaled amikacin for severe gram-negative pulmonary infections in the intensive care unit: current status and future prospects
callnumber	RC86-88.9
title_auth	Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects
abstract	Abstract Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials.
abstractGer	Abstract Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials.
abstract_unstemmed	Abstract Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1
title_short	Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects
url	https://doi.org/10.1186/s13054-018-1958-4 https://doaj.org/article/f67bf3dbc05f48c084cbe29fdc19aaee http://link.springer.com/article/10.1186/s13054-018-1958-4 https://doaj.org/toc/1364-8535
remote_bool	true
author2	Anna Motos Denise Battaglini Gianluigi Li Bassi
author2Str	Anna Motos Denise Battaglini Gianluigi Li Bassi
ppnlink	331258269
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1186/s13054-018-1958-4
callnumber-a	RC86-88.9
up_date	2024-07-03T17:51:12.270Z
_version_	1803581204487733248
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ073469041</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309115127.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2018 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s13054-018-1958-4</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ073469041</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJf67bf3dbc05f48c084cbe29fdc19aaee</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC86-88.9</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Antoni Torres</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pseudomonas aeruginosa</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Amikacin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ventilator-associated pneumonia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gram-negative bacteria</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medical emergencies. Critical care. Intensive care. First aid</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna Motos</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Denise Battaglini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gianluigi Li Bassi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Critical Care</subfield><subfield code="d">BMC, 2015</subfield><subfield code="g">22(2018), 1, Seite 6</subfield><subfield code="w">(DE-627)331258269</subfield><subfield code="w">(DE-600)2051256-9</subfield><subfield code="x">1466609X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:22</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/s13054-018-1958-4</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/f67bf3dbc05f48c084cbe29fdc19aaee</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://link.springer.com/article/10.1186/s13054-018-1958-4</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1364-8535</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">22</subfield><subfield code="j">2018</subfield><subfield code="e">1</subfield><subfield code="h">6</subfield></datafield></record></collection>
score	7.399748

Nicht das Richtige dabei?

Schreiben Sie uns!

Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?